301201 logo

ChengDa Pharmaceuticals XSEC:301201 Stock Report

Last Price

CN¥18.46

Market Cap

CN¥2.8b

7D

-0.2%

1Y

-28.0%

Updated

08 Jul, 2024

Data

Company Financials

ChengDa Pharmaceuticals Co., Ltd.

XSEC:301201 Stock Report

Market Cap: CN¥2.8b

301201 Stock Overview

Engages in the research and development, production, and sale of pharmaceutical intermediates, chemical ingredients, and food and feed additives in China and internationally.

301201 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance1/6
Financial Health6/6
Dividends2/6

ChengDa Pharmaceuticals Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for ChengDa Pharmaceuticals
Historical stock prices
Current Share PriceCN¥18.46
52 Week HighCN¥31.50
52 Week LowCN¥14.60
Beta0.16
11 Month Change-0.11%
3 Month Change-12.22%
1 Year Change-27.98%
33 Year Changen/a
5 Year Changen/a
Change since IPO-36.98%

Recent News & Updates

Recent updates

Shareholder Returns

301201CN PharmaceuticalsCN Market
7D-0.2%1.0%-1.4%
1Y-28.0%-15.1%-18.4%

Return vs Industry: 301201 underperformed the CN Pharmaceuticals industry which returned -15.1% over the past year.

Return vs Market: 301201 underperformed the CN Market which returned -18.4% over the past year.

Price Volatility

Is 301201's price volatile compared to industry and market?
301201 volatility
301201 Average Weekly Movement7.0%
Pharmaceuticals Industry Average Movement5.7%
Market Average Movement6.6%
10% most volatile stocks in CN Market10.0%
10% least volatile stocks in CN Market4.2%

Stable Share Price: 301201's share price has been volatile over the past 3 months.

Volatility Over Time: 301201's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1980529Gang Luwww.chengdapharm.com

ChengDa Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates, chemical ingredients, and food and feed additives in China and internationally. It offers APIs; bulk drugs for urogenital, musculoskeletal system, and antineoplastic and immunomodulators; and drug intermediates for blood and hematopoietic organs, digestive tract and metabolism, and nervous system. The company was founded in 1980 and is based in Jiaxing, China.

ChengDa Pharmaceuticals Co., Ltd. Fundamentals Summary

How do ChengDa Pharmaceuticals's earnings and revenue compare to its market cap?
301201 fundamental statistics
Market capCN¥2.80b
Earnings (TTM)CN¥89.98m
Revenue (TTM)CN¥412.99m

30.1x

P/E Ratio

6.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
301201 income statement (TTM)
RevenueCN¥412.99m
Cost of RevenueCN¥233.72m
Gross ProfitCN¥179.27m
Other ExpensesCN¥89.29m
EarningsCN¥89.98m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Aug 28, 2024

Earnings per share (EPS)0.59
Gross Margin43.41%
Net Profit Margin21.79%
Debt/Equity Ratio0.1%

How did 301201 perform over the long term?

See historical performance and comparison

Dividends

1.1%

Current Dividend Yield

34%

Payout Ratio

Does 301201 pay a reliable dividends?

See 301201 dividend history and benchmarks
When do you need to buy 301201 by to receive an upcoming dividend?
ChengDa Pharmaceuticals dividend dates
Ex Dividend DateJul 10 2024
Dividend Pay DateJul 10 2024
Days until Ex dividend2 days
Days until Dividend pay date2 days

Does 301201 pay a reliable dividends?

See 301201 dividend history and benchmarks
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.